Click here for prescribing information and adverse event reporting

Key Information

NaMuscla: 1st licensed antimyotonic demonstrated to control symptomatic myotonia.1-2

Functional benefits vs placebo irrespective of NDM channelopathy.1,2

NaMuscla: Suitable for long-term use.3

NaMuscla: A daily, long-term treatment for relief from myotonia.3

Product details

Contact Us

scroll to top